This phase 3 study tests whether adding an experimental immunotherapy (PDS0101) to standard pembrolizumab helps people with advanced HPV16-positive head and neck cancer live longer or delay tumor growth. About 252 adults whose cancer has spread or returned and cannot be removed b…
Phase: PHASE3 • Sponsor: PDS Biotechnology Corp. • Aim: Disease control
Last updated May 13, 2026 15:58 UTC